Navigation Links
AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
Date:3/14/2008

PASADENA, Calif., March 14 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $56,000, or break even per share basic and diluted, for the three months ended December 31, 2007, compared with a net profit of $36,000, or break even per share basic and diluted, for the three months ended December 31, 2006. For the year ended December 31, 2007, the net loss was $118,000, or $0.01 per share basic and diluted, compared with net loss of $481,000, or $0.03 per share basic and diluted for the same period in 2006. As of December 31, 2007, the Company reported $8.8 million in cash and marketable securities, the same amount reported as of December 31, 2006.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the third quarter, but results were down compared to the fourth quarter of last year. The response to marketing through The Shopping Channel in Canada is encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS recently reported that it signed a licensing and development agreement with Eli Lilly and Company granting them exclusive worldwide rights to MBP8298. AutoImmune's rights to payments and royalties are unchanged by this new agreement. Dr. Bishop remarked, "It is comforting to see Eli Lilly and Company make this commitment to commercializing MBP8298. Should the product be successful in ongoing Phase III trials, Lilly's regulatory, marketing and sales capabilities will be of gre
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 8 Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... part of the newly created Next Biotech Index of,NYSE ... our company,for this index," said Ronald Lorijn, CEO of ... companies and will help investors to track,the performance of ...
... team is proud to announce,the USDA/CVB has granted ... as well as an autogenous bacterin license utilizing ... approval of our manufacturing facility and our oral ... significant milestone for,our Company, and we look forward ...
... of Molecular Vision today,announces that discussions with Acrongenomics ... ceased. Acrongenomics has been unable to,complete on the ... of,Molecular Vision believes that the best interests of ... a conclusion. Acrongenomics remains a,significant shareholder in Molecular ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Part of Next Biotech Index 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:4/14/2014)... are continuing to unravel the molecular changes that underlie ... infections. , When the bacterium Yersinia pestis enters the ... 100 percent fatal if untreated. The way in which ... kills people in a matter of days has largely ... demonstrating that the presence of a protein called the ...
(Date:4/14/2014)... the decision of whether to get a dog. ... can be even more challenging. Now, a University ... in families of children with autism and found, ... reported the benefits of dog ownership included companionship, ... learn responsibility. , "Children with autism spectrum disorders ...
(Date:4/14/2014)... Think of the pressure change you feel when an elevator ... how you,d feel if that elevator carried you all the ... the blink of an eye. , That,s similar to what ... near a dam. For some, the change in pressure is ... seriously injured. , In an article in the March issue ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... of Insect Molecular Biology reports the detailed analyses ... pest, the Pea Aphid. The analyses are based on ... and is a major step in enhancing our understanding of ... significant plant pests. The sequencing of the Pea ...
... have calculated the energy and economic potential of urban ... slurry for generating electricity in Spain. These residues are ... friendly and, in the case of solid urban waste, ... has economic and environmental advantages. "It gives added value ...
... the launch of the first Meteosat in 1977, 33 ... given meteorologists the tools to improve weather forecasting, with ... improving with data from operational satellites, like Meteosat Second ... basis for numerical forecasts, making use of the world,s ...
Cached Biology News:Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 2Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 3Waste could generate up to 7 percent of electricity in Spain 2Waste could generate up to 7 percent of electricity in Spain 3
...
...
... designed to rapidly and reliably amplify ... patented APA Technology. APAgene provides hassle-free, ... competitive price. All necessary ingredients are ... Kit can be used for identifying ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: